One Small Step for a Patient, One Giant Leap for Orthostatic Hypotension.
Date
2022-11
Journal Title
Journal ISSN
Volume Title
Repository Usage Stats
views
downloads
Citation Stats
Attention Stats
Abstract
A 52-year-old man with ischemic cardiomyopathy presented with progressive, severe orthostatic hypotension refractory to medical therapy. Standard abdominal and leg compression devices were used without success. A novel, inflatable abdominal compression device was created that alleviated the patient's symptoms and maintained his blood pressure.
Type
Department
Description
Provenance
Subjects
Citation
Permalink
Published Version (Please cite this version)
Publication Info
Coniglio, Amanda C, Veraprapas Kittipibul, Ralph Pelligra, Eric S Richardson, Christopher L Holley and Marat Fudim (2022). One Small Step for a Patient, One Giant Leap for Orthostatic Hypotension. Cureus, 14(11). p. e31612. 10.7759/cureus.31612 Retrieved from https://hdl.handle.net/10161/28283.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
Collections
Scholars@Duke
Christopher Lee Holley
The Holley Laboratory is focused on the role of non-coding RNA (ncRNA) in cardiovascular health and disease, with a special emphasis on snoRNA (small nucleolar RNA). snoRNAs are canonically known to guide the chemical modification of other RNAs, with ribosomal RNA being the primary target. Dr. Holley’s research has helped to uncover a novel biologic role for the Rpl13a snoRNAs in the regulation of reactive oxygen species (ROS) and oxidative stress. These four snoRNAs (U32a, U33, U34, and U35a) have a critical role in the oxidative stress response to a variety of stimuli, including saturated fatty acids, lipopolysaccharide, doxorubicin, and hydrogen peroxide.
The Holley Lab has shown that at least one mechanism linking the Rpl13a snoRNAs to ROS and oxidative stress is snoRNA-guided methylation of mRNA. This methylation in an mRNA coding sequence inhibits subsequent protein translation. We have also shown that snoRNA-guided methylation alters RNA conformational ensembles, which can stabilize short-lived structures.
Currently, the lab is studying the role of Rpl13a snoRNAs in atherosclerosis, where loss or inhibition of these snoRNAs reduces athero by ~50%. We are actively pursuing translational research opportunities to design "RNA therapeutics" targeting these snoRNAs for potential clinical use.
Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.